semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Osteoarthritis, Knee Compliance with the ACR Medial knee OA defined as "No osteoarthritis", "Doubtful narrowing of joint space and/or possible osteophytes", "Definite osteophytes and possible narrowing of joint space", "Multiple osteophytes, definite narrowing of joint space and some sclerosis and deformity of bone ends". This corresponds to the Kellgren and Lawrence (KL) grades 0, 1, 2 and 3 respectively Willingness to participate in exercise and use of analgesics A maximum of 75/100 points in the KOOS Pain subscale BMI of 32 or less  Medial greater than lateral joint space width Medial knee OA of KL grade 4 Knee surgery or steroid injection within the past 6 months Already taking max dose NSAIDs or acetaminophen Any physician-determined condition that is a contraindication for use of acetaminophen, NSAIDs or to exercise Problems affecting the lower extremity overriding the problems from the knee Knee surgery planned in the next 6 months Known ACL tear within the past 6 months ACL reconstruction Diagnosis of systemic arthritis
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hypophosphatemic Rickets, X Linked Dominant age ≥18 or greater an established diagnosis of XLH fasting serum calcium ≤10.5 mg/dl fasting PTH at time of screen </= 1.7 times the upper limit of normal  estimated creatinine clearance < 60 cc/min and/or serum creatinine > 1.5 mg/dl serum 25(OH)vitamin D < 30 ng/ml. Potential study subjects who have a serum 25(OH)vitamin D < 30 ng/ml will be supplemented with 25(OH)vitamin D to achieve a serum value > 30 ng/ml and then re screened inability to comply with instructions and appropriate follow up visits treatment with agents that may skeletal metabolism such as glucocorticoids, bisphosphonates, denosumab, teriparatide, estrogen and anticonvulsants
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Obesity Patients 95% or over BMI having outpatient surgery
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Multiple Myeloma Patients must have histologically or cytologically confirmed Smoldering Multiple Myeloma confirmed by the Laboratory of Pathology, NCI based on the International Myeloma Working Group Serum M-protein greater than or equal to 3 g/dl and/or bone marrow plasma cells greater than or equal to 10 % Absence of anemia: Hemoglobin >10 g/dl Absence of renal failure: calculated creatinine clearance (according to MDRD) > 80 ml/min (or alternatively based on standard creatinine level of 2 mg/dl) Absence of hypercalcemia: Ca < 10.5 mg/dl or less than or equal to 2.5 mmol/L Absence of lytic bone lesion High-risk SMM per Mayo Clinic2 or Spanish Measurable disease within the past 4 weeks defined by any one of the following Serum monoclonal protein greater than or equal to 1.0 g/dl Urine monoclonal protein >200 mg/24 hour  Patients who are receiving any other investigational agents not included in this trial, within 21 days of the start of this trial and throughout the duration of this trial Prior therapy for SMM with a proteasome inhibitor Patients with a diagnosis of MM Contraindication to any concomitant medication, including antivirals, anticoagulation prophylaxis, tumor lysis prophylaxis, or hydration given prior to therapy Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent Uncontrolled hypertension or diabetes Pregnant or lactating females Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption Patient has greater than or equal to Grade 2 peripheral neuropathy Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-85.0,  Post Menopausal Osteoporosis Postmenopausal woman, less than 85 years old BMD T-score ≤-2.5 of spine or hip (femoral neck) or ≤-2.0 with previous fracture (within 5 years) Normal physical exam, vital signs, electrocardiogram (ECG), and medical history Laboratory tests within the normal range, including serum calcium, Vitamin D, parathyroid hormone (PTH) (1-84), serum phosphorus, and alkaline phosphatase  BMD T-score ≤-5.0 at the lumbar spine or hip History of bone disorders (for example, Paget's disease) other than postmenopausal osteoporosis Significantly impaired renal function History of any cancer
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Thumb Osteoarthritis Osteoarthritis in CMC1 diagnosed by radiography and a surgeon Planned surgery(interposition arthroplasty) in CMC1 Ability to communicate in Norwegian  Surgery involving other joints of the hand in addition to CMC1 Previous surgery of the same thumb Other diseases og injuries that could influence hand function Mental or cognitive deficit
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Chronic Kidney Disease. Patients with iPTH level > 65 pg/ml; Ca between 8.4 00 mg/dL and P between 2.9-4.5 Negative serum pregnancy test for female subjects of childbering potential Informed consent  Use vitamin D supplements Altered liver function tests (bilirubin, aminotransferases and total alkaline phosphatase > 3 times the upper limit of normal ranges) Sympthomatic cardiovascular disease on the basis of clinical history. Cancer
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hyperparathyroidism Healthy subjects with with no medical problems (n=15) and individuals with primary hyperparathyroidism (n=30) normal blood pressure or stage 1 hypertension that is either untreated, or adequately treated with a single anti-hypertensive medication Age >18 years and <80 years Estimated GFR > 60ml/min  Chronic Kidney Disease or eGFR<60 Stage 2 or Stage 3 hypertension or the use of more than 1 antihypertensive drug Type 2 Diabetes Mellitus that is not controlled by diet or Metformin alone or with a Hemoglobin A1c >7.5% History of liver failure History of heart failure The use of typical or atypical antipsychotic medications or lithium Chronic inflammatory conditions (such as inflammatory bowel disease or arthritis) that are treated with prescribed doses of NSAIDs or glucocorticoids The use of prescribed doses of potassium supplements Illness requiring overnight hospitalization in the past 6 months Active tobacco or recreational drug use
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 13.0-21.0,  Type 1 Diabetes Vitamin D Deficiency/Insufficiency Between 13 to 21 years of age, with at least Tanner stage 4 sexual maturity for males or post-menarchal females, and T1DM for at least 1 year. To ensure that for sexual maturity are met, a physical exam for research purposes will be performed. 2. HbA1c between 7 to 9% 3. Adequate renal function (serum creatinine < 1.5 mg/dL in males and < 1.2 mg/dL in females) and adequate liver function (AST and ALT < 2.5 times the upper limit of normal) 4. Vitamin D insufficiency or deficiency (25-OH vit D level < 30ng/mL) which will be determined on initial screening labs after consenting subjects  Less than 13 or greater than 21 years of age 2. Less than Tanner stage 4 sexual maturity for males or pre-menarche 3. HbA1c less than 7% or greater than 9% 4. T1DM for less than 1 year 5. Vitamin D sufficient (25-OH vit D level > 30 ng/mL) 6. Currently taking any medication that can interfere with vitamin D synthesis or metabolism, including but not limited to Orlistat, Phenobarbital, Dilantin, Anti-tuberculosis drugs 7. Currently taking any medication other than insulin that alters blood glucose levels, including but not limited to systemic glucocorticoids 8. Inadequate renal function (serum creatinine > 1.5mg/dL in males and > 1.2mg/dL in females) or inadequate liver function (AST and ALT > 2.5 times the upper limit of normal) 9. Evidence of malabsorption or short gut
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Premature Infants Born at 28 0/7 to 34 6/7 weeks PMA and 1000-2250 g birth weight Currently 34 0/7 to 38 6/7 weeks post-menstrual age at time of consent Born at Texas Children's (including Pavilion for Women) or Methodist campus hospitals or transferred within 48 hours of birth Care expected to be provided at one of these institutions until discharge home Any initial feeding will be permitted, but expected to transition to primarily (80% of feeds or up to 2 breast milk feeds per day) infant formula by 38 6/7 weeks PMA or hospital discharge, whichever comes first Able to tolerate 22 kcal/oz transitional formula and receive a volume of at least 130 mL/kg/day total feeding volume No longer receiving any form of mechanical ventilation or diuretics. Low flow nasal cannula (< ¼ LPM) will be permitted if it is anticipated this will be discontinued before hospital discharge  Bronchopulmonary dysplasia (BPD) requiring daily use of diuretics beyond 38 6/7 weeks PMA (or hospital discharge, whichever comes first) and > 22 kcal/oz concentration formula beyond 38 6/7 weeks PMA Major congenital anomalies, history of proven Stage 2 or above NEC, or severe feeding intolerance Caloric density greater than 22 kcal/oz Higher order multiples (However, twins are acceptable. Twins will be randomized together. Only data from 1 twin picked at random will be used in the final analyses.)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Dermatomyositis Adult Polymyositis Inclusion Body Myositis Myositis For Aim 1 of the study: The for myositis subjects are: -Diagnosis of PM, DM or IBM during military service. Subjects may be active duty or no longer active duty personnel. A matrix diagnosis of myositis will be based on ICD-9 and ICD-10 codes, laboratory tests and medical records in an attempt to match for probable or definite PM, DM or IBM The for matched control subjects are: -The same gender, race, age within 10 years, and service in the military within 10 years as the myositis subject. The  for control subjects are: -A matrix diagnosis of autoimmune or chronic muscle disease based on ICD-9 or ICD-10 codes and medical records. For Aims 2 and 3 of the study: The for enrollment of myositis subjects are Diagnosis of myositis during military service or service as a military contractor or civilian working for the military, based on for probable or definite PM or DM, or clinically or pathologically defined or possible IBM. Subjects may be active duty or no longer active duty personnel. Military contractors or civilians working for the military those with at least 1 year of collective service on a military base or who actively deployed with military units after October 1998 and developed myositis will be eligible for this study Able and willing to give informed consent, to complete the questionnaires and to donate blood samples. The for matched controls are Persons with military experience or having served as a military contractor or civilian working for the military attending the same clinic or hospital as the myositis subject to which they are matched, or if not available, volunteers from the general community (such as other participating military or VA hospitals, private HCPs, or the NIH Healthy volunteer program), gender race and age (within 10 years) and military service period (within 10 years) matched to the myositis subject. Military contractors those with at least 1 year of collective service on a military base or who actively deployed with military units after October 1998 Controls should be without a recognized autoimmune or chronic muscle disease, able and willing to give informed consent, to complete the questionnaires and to donate blood samples. The for all protocol subjects are Medical illness that in the judgment of the investigators does not allow safe blood draws or other clinical evaluations needed for study participation
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Glucose Metabolism Disorders Lipid Metabolism Disorders Metabolic Diseases healthy, normally active, younger (18-30 y), normal glucose tolerant subjects, without a family history of T2DM (neither parent nor siblings), and BMI of 23-26 kg/m2. 2. healthy, normally active, older (≥65 y), normal glucose tolerant subjects without a family history of T2DM, and BMI of 23-26 kg/m2. 3. Women must be non-lactating. Female patients are eligible only if they have a negative pregnancy test throughout the study period (or postmenopausal). Postmenopausal women taking hormone replacement will be included if they have been on a stable dose for ≥6 months. In younger menstruating woman, all metabolic studies will be performed on the follicular phase of the menstrual cycle. 4. Subjects must have the following laboratory values: Hematocrit ≥ 35%, serum creatinine ≤ 1.5 mg/dl, AST < 2 X upper limit of normal, ALT < 2 X upper limit of normal, alkaline phosphatase < 2 X upper limit of normal, normal urinalysis, and normal platelets, PT and PTT  Subjects with diabetes or impaired glucose tolerance based on ADA criteria. 2. Subjects taking drugs known to affect glucose and lipid homeostasis will be excluded. 3. Patients with a history of heart disease (New York Heart Classification greater than grade II; more than non-specific ST-T wave changes on the ECG), peripheral vascular disease, or pulmonary disease. 4. Recent pulmonary embolus, poorly controlled blood pressure (systolic BP>170, diastolic BP>95), resting heart rate >100, electrolyte abnormalities, neuromuscular or musculoskeletal disease. 5. Subjects who smoke
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Vestibulodynia non pregnant women between 18-35 naïve to HCs or other hormonal medications Patients able to provide Informed Consent and complete questionnaires Patient intends to use HCs for at least one year On exam before initiation of HCs, patient does not have primary PVD, pelvic floor hypertonicity, vaginismus or congenital abnormalities Patient will be available for follow up appointments Patient is willing to undergo gynecologic examination, if dyspareunia develops  Patients with endocrine disturbances (including PCOS), liver diseases and eating disorders Patients who suffer from Hypertension, Migraine with aura or clotting disturbances Patients that experience pain with intercourse or tampon insertion Patients that have other contraindications for HCs use
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Osteomalacia <TAB>Chronological age: 18-70 years 2. <TAB>Diagnosis of a genetic form of FGF23-mediated hypophosphatemia: 1. <TAB>X-linked hypophosphatemic rickets (XLH) 2. <TAB>Autosomal dominant hypophosphatemic rickets (ADHR) 3. <TAB>Autosomal recessive hypophosphatemic rickets (ARHR) Or, diagnosis of a non-genetic form of FGF23-mediated hypophosphatemia, i.e. tumor-induced osteomalacia (TIO) 3. <TAB>Ability to understand and provide informed consent 4. <TAB>Ability to complete the protocol scheduled assessments and medication regimen 5. <TAB>Women of child-bearing potential (not surgically sterile via tubal ligation, bilateral oophorectomy or hysterectomy, or who are not postmenopausal for greater than or equal to 1 year) must agree to practice adequate contraception that may but is not limited to, abstinence, monogamous relationship with vasectomized partner, barrier methods such as condoms, diaphragms, spermicides, intrauterine devices, and licensed hormonal methods for the duration of the treatment portion of the study  <TAB>Chronic or recurrent hypocalcemia defined by a serum calcium < 8.4 mg/dL (2.1 mmol/L) 2. <TAB>Tertiary hyperparathyroidism as evidenced by concurrent PTH and calcium levels above the upper limit of normal 3. <TAB>History of parathyroid surgery and/or hypoparathyroidism 4. <TAB>Hypercalciuria as defined as > 4 mg/kg/day (0.1 mmol/kg/day) on optimized conventional therapy (as determined during SOC optimization phase) 5. <TAB>Moderate to severe hepatic insufficiency as defined by total bilirubin > 2 mg/dL and serum albumin < 3 g/dL and International Normalized Ratio (INR) >2 OR presence of ascites or hepatic encephalopathy. 6. <TAB>A calculated eGFR < 50 mL/min/1.73 m(2), using the CKD-EPI equation 7. <TAB>History of a non-febrile seizure disorder 8. <TAB>History of a clinically significant cardiac arrhythmia 9. <TAB>History of chronic gastrointestinal disease 10. <TAB>Current therapy (at the time of informed consent) bisphosphonates, calcitonin, diuretics or medications that may have a significant drug interaction with cinacalcet 11. <TAB>Known hypersensitivity to cinacalcet or any of its constituents 12. <TAB>Positive pregnancy test or lactation 13. <TAB>Use of another investigational agent (i.e., in the context of a clinical trial, use of an investigational product that may have impact on the study) within the last 3 months
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Knee Pain Male & no pregnant female age between 18-40 yrs, who continue to experience knee pain following normal to Grade 2 knee arthroscopy findings  Any types of anatomical or neurological causes for the pain, history of seizures, regional pain syndrome, alcohol or drug abuse, and malignancy, patients with clinically significant diseases and patients who do not understand English will be excluded